Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-3476(84)80967-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections?
Clin Orthop Relat Res
January 2025
Department of Medicine, Duke University, Durham, NC, USA.
Background: Rifampin therapy is indicated for the treatment of staphylococcal periprosthetic joint infection (PJI) in patients who have undergone debridement, antibiotics, and implant retention (DAIR) or one-stage revision as per the Infectious Diseases Society of America (IDSA) guideline. Given the well-established effectiveness of rifampin as adjunctive therapy in staphylococcal PJI, it is crucial to evaluate its utilization in practice and identify factors that contribute to its underuse or incomplete administration, as these deviations may undermine treatment efficacy and patient outcomes.
Questions/purposes: Among patients who met clear indications for rifampin use having undergone DAIR or one-stage revision for staphylococcal PJI, (1) what proportion of patients did not receive it? (2) What proportion of patients started it but did not complete the planned course? (3) Where documented in the medical record, what were the common reasons for not using it or prematurely discontinuing it, and in what percentage of the patients' charts was no reason given? (4) What proportion of patients were taking a medication that put them at risk for a drug-drug interaction (DDI)?
Methods: Using an institutional database, patients who underwent DAIR or revision arthroplasty for PJI from January 2013 to April 2023 were identified (n = 935).
Background: When Behçet's disease is complicated with gastrointestinal ulcers, it is referred to as intestinal Behçet's disease (BD). Clinically uncommon, this condition can involve the entire gastrointestinal tract, often presenting diagnostic challenges in differentiation from Crohn's disease.
Methods: In this case, atypical BD was diagnosed through endoscopic examination, whereas latent tuberculosis infection (LBTI) was confirmed via T-SPOT and PPD tests.
Two rare cases of Brucella-induced endocarditis and myopericarditis: challenges in diagnosis.
J Infect Dev Ctries
November 2024
Clinic for Cardiology, University Clinical Center of Serbia, Koste Todorovića 8, 11000, Belgrade, Serbia.
Introduction: Brucellosis is one of the most common zoonotic infections in the world. Cardiac complications of the disease are usually in the form of endocarditis, and, to a lesser extent, in the form of myopericarditis.
Case: We report the case of a 34-year-old female admitted with signs of fever, nausea, and headache.
Deconvoluting zavegepant drug-drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics.
Clin Transl Sci
December 2024
Pfizer Inc., Groton, Connecticut, USA.
Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and P-glycoprotein [P-gp] inhibitor) on the pharmacokinetics of intranasal/oral zavegepant and the effects of rifampin (a strong inducer of CYP3A4 and P-gp; and an inhibitor of organic anion transporting polypeptide 1B3 [OATP1B3]) on oral zavegepant in healthy participants. In the intranasal/oral zavegepant-itraconazole cohort, participants received a single 10-mg dose of zavegepant nasal spray on Day 1, followed by oral zavegepant (50 mg) on Day 3.
View Article and Find Full Text PDFEvaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects.
Clin Transl Sci
November 2024
Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- SKLB1028 is a new protein kinase inhibitor being tested to treat a specific type of leukemia (FLT3-ITD mutated acute myeloid leukemia), and its metabolism was studied in clinical trials.* -
- Three studies were conducted with healthy male participants to analyze how other medications (itraconazole, gemfibrozil, and rifampin) affect the metabolism of SKLB1028, focusing on dosage and interaction effects.* -
- Results showed that itraconazole and gemfibrozil increased SKLB1028's exposure in the body, while rifampin decreased it; all drug combinations were well tolerated by participants.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!